Novartis AG v. Alembic — Entresto Patent Dispute Ends in Consent Judgment
Novartis AG brought infringement claims against Alembic and its affiliates in Delaware, asserting four patents protecting Entresto (sacubitril/valsartan) heart failure tablets. After more than four years of litigation, the parties reached a consent judgment and order of injunction — blocking Alembic from launching a generic version pending patent expiry.
Four-patent Entresto battle ends with injunction against Alembic generics
Novartis AG filed Case No. 1:20-cv-00074 in the Delaware District Court on January 17, 2020, asserting infringement of four United States patents — US8101659B2, US9388134B2, US8796331B2, and US8877938B2 — all directed to sacubitril/valsartan, the active combination sold under the Entresto brand. The accused products were Alembic’s proposed generic tablets in the three dosage strengths: 24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg. The defendants comprised Alembic (the primary entity), Alembic Global Holding SA, and Alembic Pharmaceuticals, Inc., reflecting the typical multi-entity structure of ANDA-related Hatch-Waxman litigation.
The case closed on February 7, 2024, when Judge Richard G. Andrews signed a Consent Judgment and Order of Injunction covering all three Alembic entities. A consent judgment in Hatch-Waxman litigation typically reflects a negotiated resolution in which the generic applicant agrees to be bound by the patent holder’s exclusivity through a defined entry date or patent expiry — and accepts an injunction precluding earlier commercial launch. The precise entry date and any licensing terms remain confidential and are not reflected in the public docket.
At 1,482 days — roughly four years and three weeks — this case falls within the normal range for contested ANDA patent litigation in Delaware, though it is notable that it ran alongside related multi-district litigation (1:20-md-02930-RGA) involving other Entresto generic challengers. The consent judgment, rather than a trial outcome, suggests the parties likely reached a commercial settlement on entry date, avoiding the cost and uncertainty of adjudication. What drove the specific timing of the resolution — whether claim construction outcomes, validity risk, or commercial negotiation — is not discernible from the public record.
Filing to settlement in 1482 days
Days from filing to consent judgment — over 4 years of ANDA litigation
Consent Judgment and Injunction: what it means for both parties
What a consent judgment means in ANDA litigation
A consent judgment is a court-entered order reflecting terms agreed between the parties. In Hatch-Waxman ANDA cases, it typically means the generic company accepts an injunction against launching its product before an agreed date — often tied to patent expiry or a negotiated entry date. It is not an admission of infringement, but it does bind the generic to the agreed terms with the force of a court order.
Negotiated resolutionNovartis secures injunction protecting Entresto revenue
The consent judgment and order of injunction effectively extends Novartis’s market exclusivity for Entresto against Alembic’s generic product. Entresto is one of Novartis’s highest-revenue assets in cardiovascular medicine. By securing an injunction rather than litigating to trial, Novartis preserves its patent position and avoids any adverse finding on validity or claim scope that a full trial might have produced.
Exclusivity protectedAlembic restrained from launch — but likely holds a future entry date
Consent judgments in Hatch-Waxman matters almost always include a negotiated date on which the generic may enter the market — either at patent expiry or earlier. While the specific terms are not public, Alembic’s acceptance of the injunction in exchange for a defined entry date is consistent with standard ANDA settlement practice. This preserves Alembic’s long-term interest in the sacubitril/valsartan market without the risk of an unfavourable trial ruling.
Deferred market entryCase part of broader Entresto multi-district litigation
The consent judgment expressly cross-references the Entresto MDL (1:20-md-02930-RGA) and at least two other related individual cases. This signals that Novartis pursued a coordinated enforcement strategy against multiple generic filers simultaneously. Resolution of this Alembic action is one piece of a broader patent protection campaign — and outcomes in parallel cases may differ depending on each generic’s litigation posture and entry date negotiations.
Multi-challenger enforcementFull party and counsel information
| Role | Nom | Type | Détail |
|---|---|---|---|
| Demandeur | Novartis, AG | Entreprise | Global pharmaceutical innovator — holder of four Entresto (sacubitril/valsartan) formulation patentsSearch in Eureka ↗ |
| Défendeur | Alembic | Entreprise | Indian generic pharmaceutical group pursuing U.S. ANDA for sacubitril/valsartan tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Christina Schwarz | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Jared L. Stringham | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Nicholas N. Kallas | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Plaintiff counsel | Whitney M. Howard | Attorney | Counsel for Novartis, AGSearch in Eureka ↗ |
| Defendant counsel | Amit Singhai | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant counsel | Eve H. Ormerod | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant counsel | Frank D. Rodriguez | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant counsel | Helena C. Rychlicki | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant counsel | Stuart D. Sender | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Juge en chef | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The Consent Judgment and Order of Injunction, signed by Judge Andrews on February 7, 2024, binds all three Alembic entities to its terms. The explicit inclusion of Alembic Global Holding SA alongside the U.S.-based Alembic Pharmaceuticals, Inc. is deliberate — it forecloses any attempt to circumvent the injunction through affiliated entities. The consent judgment form means no finding of infringement or validity was made; the order’s legal force derives from the parties’ agreement, not adjudication. The injunctive relief runs against commercial launch of the accused sacubitril/valsartan tablets absent further court order.
US8101659B2 and three further patents — Entresto sacubitril/valsartan formulation suite
The four asserted patents — US8101659B2, US9388134B2, US8796331B2, and US8877938B2 — collectively protect the sacubitril/valsartan combination that constitutes Entresto, a first-in-class angiotensin receptor-neprilysin inhibitor (ARNi) approved for heart failure with reduced ejection fraction. The patent family spans formulation, compound, and likely process claims, providing layered coverage across the product’s lifecycle. Application dates range from the mid-2000s through the 2010s, reflecting incremental innovation filings that extend effective exclusivity beyond the core compound patent.
Entresto has become one of the most commercially significant cardiovascular drugs globally, with multi-billion-dollar annual revenues. The four-patent assertion strategy signals that Novartis has built its IP protection in depth — any generic challenger must overcome or design around all four patents to achieve a clear launch path. The involvement of multiple ANDA filers in coordinated MDL proceedings underscores the commercial stakes and the intensity of generic competition targeting this franchise.
Should you run an FTO against the Entresto sacubitril/valsartan patent family?
Any company developing, manufacturing, or planning to commercialise a sacubitril/valsartan combination product in the United States should treat an FTO analysis against US8101659B2, US9388134B2, US8796331B2, and US8877938B2 as mandatory — not optional. The consent judgment confirms these patents remain enforceable and that Novartis is actively asserting them. R&D teams working on ARNi combinations, formulation scientists optimising sacubitril/valsartan tablet compositions, and business development teams evaluating ANDA opportunities all face direct exposure.
PatSnap Eureka’s FTO Search Agent can map all four asserted patents against your product specifications, identify claims most relevant to your formulation approach, and flag any continuation or divisional applications that may extend coverage beyond the asserted patents. Claim monitoring alerts will notify you of any new filings or term adjustments in the Entresto patent family — giving your team the earliest possible signal of changing exclusivity risk before you commit R&D or regulatory resources.
Run a freedom-to-operate analysis on US8101659B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman ANDA cases involving cardiovascular drug patents
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the cardiovascular generics IP landscape
The Entresto consent judgment reinforces how innovators use coordinated ANDA litigation and MDL consolidation to defend blockbuster cardiovascular drug patents through to expiry.
Consent judgments are Novartis’s preferred endgame in Entresto ANDA battles
The resolution by consent judgment — rather than a finding of infringement at trial — suggests Novartis is managing its patent portfolio strategically, securing injunctions while avoiding any ruling that could weaken its claim scope or validity against remaining generic challengers. Companies monitoring Entresto patent risk should track all related MDL dockets for parallel settlement patterns.
Four-patent assertion strategy creates formidable challenge for ANDA filers
Asserting four patents simultaneously — spanning formulation, compound, and process claims across multiple US patent numbers — raises the litigation cost and risk for any generic challenger. The multi-patent approach is consistent with Novartis’s documented strategy of building dense claim coverage around sacubitril/valsartan, making successful ANDA challenges materially harder and more expensive to pursue.
Novartis v Alembic — key questions answered
The case closed on February 7, 2024 via a Consent Judgment and Order of Injunction signed by Judge Richard G. Andrews in the Delaware District Court. All three Alembic entities were bound by the injunction, restraining them from commercially launching generic sacubitril/valsartan tablets without court authorisation. No trial finding of infringement or invalidity was made.
Novartis asserted four U.S. patents: US8101659B2, US9388134B2, US8796331B2, and US8877938B2. All relate to sacubitril/valsartan, the active combination in Entresto tablets (24 mg/26 mg, 49 mg/51 mg, and 97 mg/103 mg dosage strengths). The patents collectively cover formulation, compound, and related technical aspects of the product.
A consent judgment in Hatch-Waxman ANDA litigation typically means the generic company agrees to an injunction preventing launch before an agreed date — usually patent expiry or a negotiated earlier entry date. The specific entry date in the Alembic consent judgment is not public. Alembic retains the right to enter the market on that agreed date without further litigation.
Case 1:20-cv-00074 was one of several coordinated ANDA cases consolidated under MDL 1:20-md-02930-RGA before Judge Andrews in Delaware. The consent judgment expressly cross-references the MDL and at least two other related individual cases. Novartis pursued a simultaneous multi-challenger enforcement strategy against multiple generic filers, with each case potentially resolving on different terms.
Consent judgments in ANDA disputes typically reflect a commercial negotiation rather than a concession on the merits. By settling, Alembic avoids the risk of an adverse trial ruling that could affect its patent validity arguments in other contexts, secures a defined market entry date, and eliminates ongoing litigation costs. For Novartis, settlement avoids any finding that could weaken its patents against remaining generic challengers.
PatSnap Eureka searches patents and litigation data to answer instantly.